Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

N/ACompletedNCT02000102

Stanford University14 enrolled

Overview

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetic Macular Edema

Interventions

Intravitreal Injection of AfliberceptDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab - Exclusion Criteria: None \-

Locations (1)

Byers Eye Institute at Stanford

Palo Alto, California, United States

Outcomes

Primary Outcomes

Visual Acuity

Time frame: 1 year

Secondary Outcomes

Central Subfield Thickness on Optical Coherence Tomography

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.